Clinical Trials & Research

CAPE CANAVERAL, Fla., March 20, 2023. Vaxxinity, Inc., a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor contributing

On National Close the Gap Day (Thursday 16 March), Diabetes WA is calling for greater recognition of the disproportionate impact of diabetes on Aboriginal Communities in Western Australia. Aboriginal West Australians are at far greater risk of diabetes and diabetes-related complications than any other community in the State.  Image Credit: Diabetes WA Aboriginal West Australians

NEW YORK and TOKYO, March 17, 2023. Pfizer Inc. and Astellas Pharma Inc. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial

New scientific research has found that attending live sporting events improves levels of wellbeing and reduces feelings of loneliness. Published in the journal Frontiers in Public Health, the research is the first large-scale study to examine the benefits of attending any type of live sporting event. The study, carried out by academics from Anglia Ruskin

RAHWAY, N.J.–(BUSINESS WIRE) March 16, 2023 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002 is evaluating MK-7684A, a coformulation of vibostolimab, an anti-TIGIT therapy, and pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy, with or without

When it comes to cell types, stem cells have unlimited potential – literally. These self-renewing cells, which are capable of giving rise to any cell type in the body, reside in specialized microenvironments known as niches. Now, researchers in Japan have shed new insight into the dynamics of the neural stem cell niche, the home

14 March 2023 — GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. GSK’s MenABCWY vaccine candidate combines the antigenic components of its

*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. In a recent study posted to the medRxiv* preprint server, researchers at the University of North Carolina and the National Institutes of Health determined the associations between

March 6, 2023 — A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of

Pulmonary fibrosis is a devastating disease characterized by progressive scarring in the lungs, killing up to half of patients within five years of a diagnosis. Little is known about whether there are differences in how the condition affects individuals of different ethnicities. New research at the University of Chicago Medicine has found that Black patients

NEWARK, Calif., March 7, 2023. Protagonist Therapeutics, Inc. (“Protagonist” or “the Company”), today announced positive topline results from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with

Researchers at Uppsala University in Sweden are using Integra Biosciences’ PIPETBOY pro pipette controllers with integrated LED lighting to study the physiological function of mast cells and their role in allergic reactions. Their ultimate aim is to develop novel vaccines and therapies to prevent and treat common allergies. Image Credit: Integra Biosciences Related Stories The incidence of

STRATFORD, N.J., March 8, 2023. A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer’s disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate. Their findings

A recent study published in the journal Nature Immunology discovered autoantibodies against chemokines following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The spectrum of coronavirus disease 2019 (COVID-19) manifestation is broad, with convalescent subjects reporting protracted symptoms, a condition termed post-acute sequelae of COVID-19 (PASC) or long COVID. Some evidence suggests the role of

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023. Harbour BioMed (the “Company”), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announces the positive topline results of its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis

In a recent study published in the journal Nature, researchers devised a non-invasive optogenetic and wearable cardiac pacemaker for accurate and specific control of cardiac rhythm for ≤900 beats per minute (bpm), enabled by micro-light-emitting display (LED) harness and systemic channelrhodopsin delivery. Studies have reported an increase in heart rate as a result of anxiety. However,

KING OF PRUSSIA, Pa., Feb. 26, 2023 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today presented results from the pivotal placebo-controlled Phase 3 VANGUARD clinical trial of garadacimab (CSL312). Garadacimab is CSL’s investigational first-in-class monoclonal antibody being developed as a long-term prophylactic treatment for patients with hereditary angioedema (HAE). Results from the trial, the

In a recent study published in the Canadian Journal of Cardiology, researchers assessed the association between cardiovascular disease and transportation noise. Study: Too loud to handle?: transportation noise and cardiovascular disease. Image Credit: bibiphoto/Shutterstock The number of studies indicating adverse health impacts as a result of traffic noise is on a steady rise, with cardiovascular

CHICAGO, March 1, 2023. Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of Tourette Syndrome. Participants in the trial receive ecopipam for 12 weeks in the open-label phase of the study. Those with at least a 25% reduction in the Yale Global Tic

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results, published today in the New England Journal of Medicine, are from a research study led

JUPITER, Fla. and BOSTON, Feb. 27, 2023. Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline focused on the treatment of central nervous system (CNS) disorders and rare diseases, today announced topline proof-of-concept preclinical data with its proprietary resveratrol drug product, JOTROL, for Parkinson’s Disease (PD). In collaboration with scientists

A new Rare Diseases Action Plan for England will be published today (Tuesday 28 February) that will ensure those living with these conditions receive better care and treatment, fairer access to testing and have continued support. This builds on the first ever Rare Diseases Action Plan for England published in 2022 which has developed digital

COVINGTON, Ky., Feb. 23, 2023. Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today results from their clinical trial entitled, “An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors (KOURAGE)” have been

Announcing a new publication for Acta Materia Medica journal. The compound 7-ethyl-10-hydroxy-camptothecin (SN38) is a broad-spectrum antitumor agent whose applications are greatly limited by its poor solubility. Therefore, irinotecan, the hydrophilic derived prodrug of SN38, has been developed as the commercial formulation Campto® for colorectal cancer. However, only 1% to 0.1% of irinotecan is converted

PANGYO, South Korea, Feb. 24, 2023. Oscotec Inc. announced topline results for Phase 2 trial evaluating the efficacy, safety and tolerability of cevidoplenib (SYK inhibitor) in immune thrombocytopenia (ITP) patients who have failed to respond or relapsed after prior therapy. Cevidoplenib was evaluated in a 61-participant randomized, placebo-controlled trial to access its efficacy, safety, tolerability,

Researchers from the University of Queensland have identified that a gene associated with an increased risk of Parkinson’s Disease also contributes to a build-up of cell debris in the brain. Dr Adekunle Bademosi from The Queensland Brain Institute said the discovery could change the focus of Parkinson’s Disease treatment. Our team has found that a

TOKYO, Feb. 22, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical trial evaluating the safety, tolerability and exploratory efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD). The data will

One of the ironies of old age is that the more care and support we need, the harder it can be to access it, given increasing limitations in mobility and independence. Now, research from Japan reports that a governmental initiative to shift healthcare from hospitals into the community is alleviating this burden for an increasing